RACHEL CATEVENIS: Open Payments
NPI 1225583735 · SANTA BARBARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,556 in 61 payments from 13 companies in 2025. Trend: 2023 $183 · 2024 $847 · 2025 $1,556
Food & beverage: $1,472Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 10 | $317 |
| ABBVIE INC. | 11 | $241 |
| Madrigal Pharmaceuticals | 3 | $182 |
| Regeneron Healthcare Solutions, Inc. | 8 | $154 |
| Phathom Pharmaceuticals, Inc. | 7 | $140 |
| Ardelyx, Inc. | 4 | $117 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $112 |
| Aimmune Therapeutics, Inc. | 3 | $86 |
| PFIZER INC. | 3 | $74 |
| Gilead Sciences, Inc. | 2 | $48 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, VOQUEZNA, RINVOQ, IBSRELA, XIFAXAN, ZENPEP.
Industry payments across CA — which companies pay providers there.
